3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
4
Neoplasms
3
Smoking Cessation
2
Smoking
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Hematopoietic and Lymphoid System Neoplasm
1
Hematopoietic and Lymphatic System Neoplasm
1
Depression
1
Colonic Neoplasms
1
Cancer Patients
1
Anxiety Disorders
1
Advanced Malignant Solid Neoplasm
1
Interventions
Oxaliplatin
27
Fluorouracil
23
Leucovorin
22
Cetuximab
22
Bevacizumab
21
Nivolumab
16
Capecitabine
16
Irinotecan
15
pembrolizumab
11
Magnetic Resonance Spectroscopy
11
Specimen Handling
10
encorafenib
8
Folfox protocol
7
trifluridine tipiracil drug combination
6
Ipilimumab
6
Exercise
6
fludarabine
5
cemiplimab
5
Trastuzumab
5
Gemcitabine
5
Cyclophosphamide
5
Cisplatin
5
Blood Specimen Collection
5
Biopsy
5
regorafenib
4
pertuzumab
4
adagrasib
4
Trifluridine
4
Pemetrexed
4
Immune Checkpoint Inhibitors
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
Mindfulness
×
1 year
×
Clear all
NCT06323421
2025-11-21
MindCRC
University of Illinois at Chicago
Phase NA
Completed
24 enrolled